ABN.AS: $40.75 ▲ 0.30 (0.74%)DSFIR.AS: $99.66 ▼ -0.99 (-0.98%)GMAB.CO: $2,487.00 ▲ 42.00 (1.72%)REP.MC: $29.21 ▼ -0.31 (-1.05%)SOON.SW: $267.80 ▲ 3.20 (1.21%)CRWD: $263.34 ▼ -11.70 (-4.25%)HPE: $70.10 ▼ -3.36 (-4.57%)AMD: $590.61 ▼ -17.49 (-2.88%)DELL: $574.44 ▼ -11.62 (-1.98%)PANW: $399.92 ▼ -18.86 (-4.50%)MRNA: $214.33 ▼ -10.67 (-4.74%)AAPL: $339.63 ▲ 2.99 (0.89%)AMZN: $259.90 ▼ -2.53 (-0.96%)MSFT: $540.03 ▲ 4.96 (0.93%)NVDA: $226.58 ▼ -2.70 (-1.18%)CIEN: $403.01 ▼ -46.76 (-10.40%)DDOG: $288.28 ▼ -4.98 (-1.70%)SNPS: $503.23 ▼ -6.77 (-1.33%)CAP.PA: $115.35 ▲ 0.30 (0.26%)TSCO.L: $511.00 ▲ 7.20 (1.43%)WKL.AS: $77.16 ▲ 2.16 (2.88%)

Company Details

Bionano Genomics, Inc.

BNGO - NASDAQ

Identifiants & Marche

Ticker BNGO
ISIN US09075F3055
CIK 0001411690
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.